Future investigations should focus on elucidating the mechanisms of ICAM1 and CXCL12 and assessing their clinical utility in PD, thereby providing new avenues for early diagnosis and targeted therapeutic strategies. This evidence concerns the gene ICAM1 and Parkinson disease.